BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wang X, Zhang CS, Dong XY, Hu Y, Duan BJ, Bai J, Wu YY, Fan L, Liao XH, Kang Y, Zhang P, Li MY, Xu J, Mao ZJ, Liu HT, Zhang XL, Tian LF, Li EX. Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2022; 14(7): 1252-1264 [PMID: 36051096 DOI: 10.4251/wjgo.v14.i7.1252]
URL: https://www.wjgnet.com/1948-5204/full/v14/i7/1252.htm
Number Citing Articles
1
Guocheng Zhong, Xiaomin Zhang, Zheng Guo, Yujie Gao, Bochen Zhao, Xianhao Liu, Lei Chen, Jingqiao Qiao, Chuan Yu, Lixin Wang, Yisheng Li, Li Yu. Complete remission of advanced pancreatic cancer induced by claudin18.2-targeted CAR-T cell therapy: a case reportFrontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1325860
2
Caroline Hana, Nyein Nyein Thaw Dar, Michael Galo Venegas, Michel Vulfovich. Claudins in Cancer: A Current and Future Therapeutic TargetInternational Journal of Molecular Sciences 2024; 25(9): 4634 doi: 10.3390/ijms25094634
3
Tongxin Zhang, Zilong He, Yankui Liu, Linfang Jin, Teng Wang. High Expression of CLDN 18.2 is Associated with Poor Disease-Free Survival of HER-2 Positive Gastric CancerInternational Journal of General Medicine 2024; : 1695 doi: 10.2147/IJGM.S453883
4
Tessa De Pauw, Lynn De Mey, Jens M. Debacker, Geert Raes, Jo A. Van Ginderachter, Timo W.M. De Groof, Nick Devoogdt. Current status and future expectations of nanobodies in oncology trialsExpert Opinion on Investigational Drugs 2023; 32(8): 705 doi: 10.1080/13543784.2023.2249814
5
Chiara Deiana, Margherita Agostini, Giovanni Brandi, Elisa Giovannetti. The trend toward more target therapy in pancreatic ductal adenocarcinomaExpert Review of Anticancer Therapy 2024;  doi: 10.1080/14737140.2024.2357802
6
Yuming Wang, Yike Gao, Zhiwen Zhang, Zixin Zhang, Anqi Wang, Kun Zhao, Miao Zhang, Sumei Zhang, Mei Li, Jian Sun, Dan Guo, Zhiyong Liang. Claudin18.2 expression in pulmonary mucinous adenocarcinomaJournal of Cancer Research and Clinical Oncology 2023; 149(14): 12923 doi: 10.1007/s00432-023-05150-x
7
Pankti C. Balar, Vasso Apostolopoulos, Vivek P. Chavda. A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the wayEuropean Journal of Pharmacology 2024; 969: 176451 doi: 10.1016/j.ejphar.2024.176451
8
Annalisa Schirizzi, Aram Arshadi, Doron Tolomeo, Laura Schirosi, Anna Maria Valentini, Giampiero De Leonardis, Maria Grazia Refolo, Rossella Donghia, Clelia Tiziana Storlazzi, Alfredo Zito, Angela Dalia Ricci, Simona Vallarelli, Carmela Ostuni, Maria Bencivenga, Giovanni De Manzoni, Caterina Messa, Raffaele Armentano, Gianluigi Giannelli, Claudio Lotesoriere, Rosalba D’Alessandro. VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based TreatmentBiomedicines 2023; 11(10): 2721 doi: 10.3390/biomedicines11102721
9
Chen Wang, Na Wu, Beibei Pei, Xiaoyan Ma, Wenhui Yang. Claudin and pancreatic cancerFrontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1136227
10
Marta Łukaszewicz-Zając, Barbara Mroczko. Claudins—Promising Biomarkers for Selected Gastrointestinal (GI) Malignancies?Cancers 2023; 16(1): 152 doi: 10.3390/cancers16010152
11
Jinxia Chen, Zhiyuan Xu, Can Hu, Shengjie Zhang, Mengli Zi, Li Yuan, Xiangdong Cheng. Targeting CLDN18.2 in cancers of the gastrointestinal tract: New drugs and new indicationsFrontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1132319
12
Izuma Nakayama, Changsong Qi, Yang Chen, Yoshiaki Nakamura, Lin Shen, Kohei Shitara. Claudin 18.2 as a novel therapeutic targetNature Reviews Clinical Oncology 2024; 21(5): 354 doi: 10.1038/s41571-024-00874-2